丁丙诺啡市场：依应用、给药途径、配销通路及地区

2023年全球丁丙诺啡市场估计为55.2亿美元，预计在预测期内（2023-2030年）复合年增长率为14.9%。

图 1. 2023 年丁丙诺啡全球市场占有率(%)，依应用分类

丁丙诺啡成为第一种在医生诊所开处方和分发的用于治疗阿片类药物使用障碍的药物，大大扩大了医疗保健的覆盖范围。与治疗中使用的所有药物一样，丁丙诺啡应作为全面治疗计划的一部分开出，其中包括咨询和其他服务，为患者提供整体治疗方法。丁丙诺啡为阿片类药物使用疾患患者以及阿片类药物治疗中心的治疗感到不舒服或不合适的患者提供了许多好处。

以下丁丙诺啡产品已获得美国FDA核准用于治疗鸦片类药物使用障碍。

• 非专利药丁丙诺啡/纳洛酮舌下片
• 丁丙诺啡舌下片（Subutex）
• 丁丙诺啡/纳洛酮舌下膜（suboxone）
• 丁丙诺啡/纳洛酮舌下片（Zubsolve）
• 丁丙诺啡/纳洛酮口腔膜（Bunavale）
• 丁丙诺啡植入（普布啡）
• 丁丙诺啡缓释注射液（Subrocade）

市场动态

增加对丁丙诺啡皮下使用的监管核准预计将在预测期内扩大全球丁丙诺啡市场。例如，2018年3月，製药公司Indivior PLC宣布皮下注射用SUBLOCADE（丁丙诺啡缓释）注射液（CIII）现已在美国上市。美国食品药物管理局(FDA) 已批准使用 Sublocade 治疗中度至重度鸦片类药物使用障碍 (OUD) 的成年患者，这些患者已开始使用含丁丙诺啡的粘膜製剂治疗，并已调整剂量至少7天，核准。丁丙诺啡只能由医疗专业人员给药，并且应该成为综合治疗计划的一部分，其中还包括咨商和社会心理支持。

本研究的主要特点

• 本报告对全球丁丙诺啡市场进行了详细分析，并介绍了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率（CAGR%）。
• 它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
• 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
• 它根据公司亮点、产品系列、主要亮点、财务实绩和策略等参数，介绍了全球丁丙诺啡市场的主要企业。
• 该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出资讯的决策。
• 全球丁丙诺啡市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
• 相关人员可以透过用于分析全球丁丙诺啡市场的各种策略矩阵来促进决策。

目录

第一章 研究目的与假设

• 研究目标
• 假设
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

• 市场动态
  • 促进因素
  • 抑制因素
  • 市场机会
• 影响分析
• 主要亮点
• 产品发表会
• 技术进步
• PEST分析
• 监管场景
• 併购

第四章全球丁丙诺啡市场 - COVID-19 疾病的影响分析

• 经济影响
• 新型冠状病毒感染疾病（COVID-19）的流行病学
• 对需求和供给的影响

第五章全球丁丙诺啡市场，依应用分类，2018-2030

• 介绍
• 止痛药
• 阿片拮抗

第六章 全球丁丙诺啡市场，依给药途径，2018-2030

• 介绍
• 注射
• 舌下
• 经皮的

第 7 章全球丁丙诺啡市场，依配销通路划分，2018-2030

• 介绍
• 医院药房
• 零售药房
• 线上药房

第八章全球丁丙诺啡市场，依地区，2018-2030

• 介绍
• 北美洲
• 美国
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲
• 欧洲
• 英国
• 德国
• 义大利
• 法国
• 西班牙
• 俄罗斯
• 欧洲其他地区
• 亚太地区
• 中国
• 印度
• 日本
• 东南亚国协
• 澳洲
• 韩国
• 其他亚太地区
• 中东
• 海湾合作委员会国家
• 以色列
• 其他中东地区
• 非洲
• 北非
• 中部非洲
• 南非

第9章竞争形势

• Mallinckrodt
• Noramco
• Unichem Laboratories Ltd.
• Sanofi
• Johnson Matthey
• Arevipharma Gmbh
• Resonance Laboratories Pvt. Ltd.
• Sun Pharmaceutical Industries Limited
• Rusan Pharma Ltd.
• Micro Orgo Chem
• Faran Shimi Pharmaceutical
• Indivior PLC
• Titan Pharmaceuticals, Inc.
• Hikma Pharmaceuticals PLC.

第10章

• 调查方法
• 关于出版商

The global buprenorphine market is estimated to be valued at US$ 5.52 Billion in 2023 and is expected to exhibit a CAGR of 14.9% during the forecast period (2023-2030).

Figure 1. Global Buprenorphine Market Share (%), by Application, 2023

Buprenorphine is the first medication to treat opioid use disorder that may be prescribed or distributed in doctor's offices, vastly expanding access to care. Buprenorphine should be prescribed as a component of a thorough treatment plan that includes counseling and other services to give patients a whole-person approach, as is the case with all drugs used in therapy. Buprenorphine provides a number of benefits for those with opioid use disorder and for those for whom therapy at an opioid treatment center is uncomfortable or inappropriate.

The following buprenorphine products are approved for the treatment of opioid use disorder by the U.S. FDA:

• Generic buprenorphine/naloxone sublingual tablets
• Buprenorphine sublingual tablets (Subutex)
• Buprenorphine/naloxone sublingual films (Suboxone)
• Buprenorphine/naloxone sublingual tablets (Zubsolv)
• Buprenorphine/naloxone buccal film (Bunavail)
• Buprenorphine implants (Probuphine)
• Buprenorphine extended-release injection (Sublocade)

Market Dynamics

Increasing approval of buprenorphine by regulatory authorities for subcutaneous use is expected to increase the global buprenorphine market over the forecast period. For instance, in March, 2018, Indivior PLC, a pharmaceutical company, announced that SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use (CIII), is available in the U.S. The U.S. Food and Drug Administration (FDA) has granted approval for the use of SUBLOCADE for the treatment of moderate to severe opioid use disorder (OUD) in adult patients who have started therapy with a transmucosal buprenorphine-containing medication and have undergone dose titration for at least seven days. It should only be given by medical professionals, and it should be part of a comprehensive treatment plan that also includes counseling and psychosocial support.

Key features of the study:

• This report provides in-depth analysis of the global buprenorphine market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global buprenorphine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study are Mallinckrodt, Noramco, Unichem Laboratories Ltd., Sanofi, Johnson Matthey, Arevipharma Gmbh, Resonance Laboratories Pvt. Ltd., Sun Pharmaceutical Industries Limited, Rusan Pharma Ltd. Micro Orgo Chem, Faran Shimi Pharmaceutical, Indivior PLC, Titan Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC.
• Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global buprenorphine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global buprenorphine market

Detailed Segmentation:

• By Application:
  • Analgesic
  • Opioid Antagonist
• By Route of Administration:
  • Injectables
  • Sublingual
  • Transdermal
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles
  • Mallinckrodt
  • Noramco
  • Unichem Laboratories Ltd.
  • Sanofi
  • Johnson Matthey
  • Arevipharma Gmbh
  • Resonance Laboratories Pvt. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Rusan Pharma Ltd.
  • Micro Orgo Chem
  • Faran Shimi Pharmaceutical
  • Indivior PLC
  • Titan Pharmaceuticals, Inc.
  • Hikma Pharmaceuticals PLC.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Application
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Key Highlights
• Product Launch
• Technological Advancements
• PEST Analysis
• Regulatory Scenario
• Mergers and Acquisitions

4. Global Buprenorphine Market- COVID-19 Impact Analysis

• Economic Impact
• COVID-19 Epidemiology
• Impact on Supply and Demand

5. Global Buprenorphine Market, By Application, 2018-2030, (US$ Billion)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019 - 2030
  • Segment Trends
• Analgesic
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
• Opioid Antagonist
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

6. Global Buprenorphine Market, By Route of Administration, 2018-2030, (US$ Billion)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019 - 2030
  • Segment Trends
• Injectables
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
• Sublingual
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
• Transdermal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

7. Global Buprenorphine Market, By Distribution Channel, 2018-2030, (US$ Billion)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019 - 2030
  • Segments Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

8. Global Buprenorphine Market, By Region, 2018-2030, (US$ Billion)

• Introduction
  • Market Share Analysis, By Region, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2018-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Billion)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• Mallinckrodt
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Noramco
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Unichem Laboratories Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Johnson Matthey
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Arevipharma Gmbh
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Resonance Laboratories Pvt. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sun Pharmaceutical Industries Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Rusan Pharma Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Micro Orgo Chem
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Faran Shimi Pharmaceutical
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Indivior PLC
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Titan Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Hikma Pharmaceuticals PLC.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section

• Research Methodology
• About Us